Strengthens Viatris' Presence in Japan With the Addition of Two Innovative Assets Targeting Areas of Significant Unmet Medical Need Leverages Existing Infrastructure and Expertise in Central...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in November 2025. The Company will participate in...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that it has been named to Forbes' list of World's Best Employers 2025. This is the fifth year in a row that Viatris has...

Viatris Inc. (Nasdaq: VTRS) will report third quarter 2025 financial results on Thursday, November 6, 2025. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the...

Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced the appointment of Andrew Enrietti as Chief Administrative and Transformation Officer. In this newly created role,...

Approval is Another Milestone of Viatris' Ability to Successfully Develop Complex Generic Medicines Approval Granted with Competitive Generic Therapy Eligibility for 100mg/5mL and 200mg/10mL...

Delivers Total Revenues Above Expectations Reflecting the Strength of our Execution and the Resilience of our Diversified Global Business Positive Results From Five Phase 3 Data Readouts This Year...

Viatris Inc. (Nasdaq: VTRS) today announced that on August 4, 2025, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's...